Kalandavis LLC

PRO Pharmaceuticals, based in Newton Center, MA, specializes in innovative cancer therapies, particularly through its carbohydrate-based drug enhancement formulation known as DAVANAT. The company is actively engaged in clinical trials for cancer treatment, including Phase I studies at notable cancer centers such as the Norris Cotton Cancer Center and Ochsner Cancer Institute. With a focus on advancing research, PRO Pharmaceuticals has appointed experts to its Scientific Advisory Board and has received patent allowances for its carbohydrate linker technology. The organization is committed to enhancing existing cancer drugs, reflected in its ongoing multi-center clinical trials targeting various solid tumors. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website